Particle Sciences, a provider of drug development services, focuses on emulsions, gels, micro and nano-particulates, drug/device combination products and potent compounds across all dosage forms.
Particle Sciences CEO Mark Mitchnick said the company is applying advanced drug delivery and formulation technologies to an established pediatric product category.
Pernix President and CEO Cooper Collins said the company is working with Particle Sciences for the product candidate, which may be another opportunity to further expand its pediatric product line.